(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 July 2019 (18.07.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/139886 A1

(51) International Patent Classification:
A01N 63/02 (2006.01) *A61K 38/16* (2006.01)
A61K 35/76 (2015.01) *A61K 38/17* (2006.01)
A61K 38/03 (2006.01) *A61K 39/12* (2006.01)

(21) International Application Number:
PCT/US2019/012659

(22) International Filing Date:
08 January 2019 (08.01.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/615,183 09 January 2018 (09.01.2018) US
62/681,458 06 June 2018 (06.06.2018) US
62/746,649 17 October 2018 (17.10.2018) US

(71) Applicant: **REALTA HOLDINGS, LLC** [US/US]; 427 West 20th Street, Norfolk, VA 23517 (US).

(72) Inventors; and

(71) Applicants: **KRISHNA, Neel, K.** [US/US]; 5220 Powhatan Avenue, Norfolk, VA 23508 (US). **CUNNION, Kenji** [US/US]; 915 Larchmont Crescent, Norfolk, VA 23508 (US).

(74) Agent: **RUBE, Daniel, A.** et al.; Troutman Sanders, LLP, 875 Third Avenue, 17th Floor, New York, NY 10022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: PIC1 INHIBITION OF MYELOPEROXIDASE OXIDATIVE ACTIVITY IN AN ANIMAL MODEL




Fig. 15

(57) Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.

WO 2019/139886 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*